Ozempic Vs Mounjaro: What Is The Difference Between These Diabetes Management And Weight Loss Drugs?

Mounjaro vs Ozempic Know the key differences between these FDA-approved diabetes and weight loss drugs. Learn about benefits, side effects, dosage, and which may be right for you.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are two injectable medications which have received considerable attention in the sphere of medicine treatment of type 2 diabetes and weight management. They are both of the category glucagon-like peptide-1 (GLP-1) receptor agonists but various in their mechanism of action, efficacy, adverse effects, and regulatory approvals.

Mechanism of Action

The first of its kind is a dual GIP (glucose dependent insulinotropic polypeptide) and GLP-1-receptor agonist's Mounjaro. It imitates the action of two hormones that may have a part in testing the secretion of insulin, glucose and fundamentally hunger.

Ozempic is a GLP-1 receptor agonist, which is an activator of the GLP-1 receptor, which prompts the insulin release in response to food intake, stops the release of glucagon, and satiates hunger.

Effectiveness in Diabetes Management and Weight Loss

• Blood Sugar Control: Clinical trials had proven that Mounjaro results in more significant levels of HbA1c reduction than Ozempic. In the SURPASS-2 trial, Mounjaro reported a reduction of 2.01, 2.24 and 2.3 at doses of 5mg, 10mg, 15mg, respectively, as compared to Ozempic of 1.86 at a dose of 1mg.
• Weight Loss: A study in the Journal of American Medicine, Mounjaro reveals that patients lose an average of 15.3 percent of their body weight between 12 months, which was higher than 8.3 percent in case of Ozempic.

Side Effects

The two drugs are similar and have side effects such as nausea, vomiting, diarrhea, abdominal pain, and constipation. However, Mounjaro can offer a little more serious adverse events rates in relation to Ozempic.

Regulatory Approvals

1. Mounjaro: FDA approved May 2022 to treat type 2 diabetes. Not yet medically proven itself to be useless in the weight loss regime, it is nonetheless finding more and more application in the off label form of weight loss.
2. Ozempic: Oral hypoglycemic therapy for type 2 diabetes is approved and has demonstrated its potential in reducing the risk of cardiovascular system.

A more intense formulation of semaglutide, called Wegovy and administered as a weight-loss drug, has been approved by the FDA.

Cost and Accessibility

Generally, Mounjaro costs more than Ozempic, and its use as an off-label weight loss drug might not be insurance covered. Although also expensive, Ozempic has an analogue, Wegovy, approved by the FDA to manage weight, and it is possibly more convenient in that respect.

Drug prescriptions follow a consultation with a healthcare professional when an individual should be identified to prescribe the most appropriate drug, according to their health conditions and therapy goals.